We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Waters Expands Accessibility to High Resolution MS Data with the First SmartMS-Enabled LC-MS Biopharma System
Product News

Waters Expands Accessibility to High Resolution MS Data with the First SmartMS-Enabled LC-MS Biopharma System

Waters Expands Accessibility to High Resolution MS Data with the First SmartMS-Enabled LC-MS Biopharma System
Product News

Waters Expands Accessibility to High Resolution MS Data with the First SmartMS-Enabled LC-MS Biopharma System

Waters Expands Accessibility to High Resolution MS Data with the First SmartMS-Enabled LC-MS Biopharma System

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Waters Expands Accessibility to High Resolution MS Data with the First SmartMS-Enabled LC-MS Biopharma System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Waters Corporation introduced the BioAccord™ System, a purposefully designed liquid chromatography-mass spectrometry (LC-MS) solution that will expand access to high-resolution time-of-flight mass spectrometry capabilities to more scientists. The BioAccord System promises to move routine monitoring out of centralized MS labs and into the hands of more scientists by enabling more effective analysis of biotherapeutic protein attributes across development and within quality control organizations.

"The pace of innovation in the biopharmaceutical industry is accelerating, and with it, the monitoring requirements for biotherapeutics are growing exponentially," said Chris O'Connell, Chairman and CEO, Waters Corporation. "The inherent complexity of these therapies, combined with rising regulatory standards, are driving more intensive and widespread testing requirements. Waters designed the BioAccord System as a fit-for-purpose LC-MS biopharmaceutical solution to deliver rich mass spectrometry data for improved productivity and effective decision-making."

The BioAccord System pairs ACQUITYTM UPLC™ I-Class Plus with the newly-developed ACQUITY RDa™ Detector featuring SmartMS™. This system offers new levels of user experience with automated setup and self diagnosis delivered through an intuitive user interface, all within a surprisingly small footprint. Powered by UNIFI™, Waters’ compliance-ready LC-MS informatics platform, the BioAccord System has been optimized for intact protein, released glycan, and peptide monitoring applications, and streamlined by the use of Waters' application-specific chemistries and consumables kits.
Advertisement